Historial de ingresos, beneficios y flujo de caja según los estados financieros oficiales.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.
Ver gráficos interactivos y estados completos → Modelo de valoración (DCF) →
| Cuenta de resultados | TTM → 2026-06-30 | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 | 2018-06-30 | 2017-06-30 | 2016-06-30 | 2015-06-30 | 2014-06-30 | 2013-06-30 | 2012-06-30 | 2011-06-30 | 2010-06-30 | 2009-06-30 | 2008-06-30 | 2007-06-30 | 2006-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos totales | $1.2B | $1.2B | $1.2B | $1.2B | $1.1B | $1.1B | $931M | $739M | $714M | $643M | $563M | $499M | $452M | $358M | $311M | $315M | $290M | $269M | $264M | $257M | $223M | $203M |
| Beneficio bruto | $798M | $799M | $790M | $770M | $770M | $756M | $633M | $483M | $473M | $432M | $375M | $337M | $307M | $251M | $231M | $236M | $225M | $215M | $208M | $205M | $177M | $157M |
| % de margen bruto | 65.7% | 65.8% | 64.8% | 66.4% | 67.7% | 68.4% | 68.0% | 65.4% | 66.3% | 67.2% | 66.5% | 67.5% | 67.9% | 70.3% | 74.4% | 75.0% | 77.6% | 79.8% | 79.0% | 79.5% | 79.1% | 77.4% |
| Ingresos operativos (EBIT) | $272M | — | $102M | $207M | $299M | $297M | $237M | $157M | $126M | $136M | $122M | $151M | $147M | $160M | $158M | $166M | $163M | $156M | $151M | $144M | $124M | $109M |
| % de margen operativo | 22.4% | — | 8.4% | 17.8% | 26.3% | 26.8% | 25.5% | 21.3% | 17.6% | 21.2% | 21.6% | 30.2% | 32.5% | 44.6% | 51.0% | 52.8% | 56.2% | 58.1% | 57.1% | 56.0% | 55.5% | 53.5% |
| Ingresos netos | $182M | $182M | $73M | $168M | $285M | $272M | $140M | $229M | $96M | $125M | $77M | $104M | $108M | $111M | $113M | $112M | $112M | $110M | $105M | $104M | $85M | $73M |
| % de margen neto | 15.0% | 15.0% | 6.0% | 14.5% | 25.1% | 24.6% | 15.1% | 31.0% | 13.5% | 19.5% | 13.7% | 20.9% | 23.8% | 31.0% | 36.2% | 35.7% | 38.7% | 40.8% | 39.9% | 40.2% | 38.1% | 36.2% |
| EBITDA | — | — | $217M | $313M | $457M | $414M | $250M | $378M | $212M | $201M | $182M | $193M | $184M | $179M | $173M | $175M | $174M | $165M | $159M | $152M | $137M | $115M |
| Beneficio por acción (EPS) | $1.16 | $1.16 | $0.46 | $1.05 | $1.76 | $1.66 | $0.87 | $1.45 | $0.62 | $0.82 | $0.52 | $0.70 | $0.72 | $0.75 | $0.76 | $0.76 | $0.76 | $0.73 | $0.69 | $0.66 | $0.54 | $0.46 |
| Acciones en circulación (M) | — | — | 160M | 161M | 162M | 164M | 162M | 158M | 156M | 152M | 150M | 149M | 149M | 148M | 148M | 148M | 149M | 149M | 152M | 157M | 158M | 158M |
Fuente: informes públicos de la empresa (SEC). Verifique en SEC EDGAR antes de confiar en cualquier cifra.
Balances, flujos de caja, datos trimestrales y ratios completos en el visor interactivo de TECH. /companies/us/TECH
La información de este sitio es solo educativa e informativa; no constituye asesoramiento de inversión. No se publican precios objetivo ni recomendaciones.
About TickerBase · Data methodology & sources · Privacy · Terms